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Abstract
Background and purpose The optimal chemotherapeutic
protocol for the treatment of esophageal cancer has not yet
been established. A dose-escalation study of docetaxel
combined with cisplatin and 5-ﬂuorouracil (5-FU) was
performed to determine the optimal dose in patients with
advanced esophageal squamous cell carcinoma.
Patients and method We studied a total of 18 patients
who had previously untreated thoracic esophageal squa-
mous cell carcinoma with T4 tumors and/or metastasis. The
patients received an infusion of docetaxel at different dose
levels (levels 1, 2, 3: 30, 35, 40 mg/m
2, respectively) and
an infusion of cisplatin (40 mg/m
2) on days 1 and 15 plus a
continuous infusion of 5-FU (400 mg/m
2/day) on days 1–5
and 15–19.
Results Dose-limiting toxicities (DLT) included febrile
neutropenia and leukopenia. DLT occurred in 2 of 6
patients at level 1, 2 and in 3 of 6 patients at level 3. The
response rate was 88.9%, including a complete response
rate of 33.3%.
Conclusions To minimize toxicity and maximize dose
intensity, we elected to investigate a biweekly regimen.
The maximum tolerated dose was level 3, and the recom-
mended dose was determined to be docetaxel 35 mg/m
2
with cisplatin 40 mg/m
2 plus 5-FU 400 mg/m
2, adminis-
tered biweekly. This regimen was tolerable and highly
active. A phase II study has been started.
Keywords Chemotherapy  Docetaxel  Cisplatin 
5-Fluorouracil  Esophageal carcinoma
Introduction
Locally advanced esophageal carcinoma is often refractory
to current therapeutic approaches, and its prognosis is grim
[1, 2]. Patients with unresectable or inoperable disease
are usually treated with chemotherapy. Although various
chemotherapy regimens are available, esophageal cancer
carries a very poor prognosis, with a mean survival time of
less than 8.1 months with current chemotherapies used
singly or in combination with 5-ﬂuorouracil (5-FU), vin-
desine, mitomycin, docetaxel, paclitaxel, cisplatin, irino-
tecan, vinorelbine, or capecitabine [3]. Fluorouracil and
cisplatin combination therapy (FP) is regarded as standard
[4], for which the median survival time is reported to be
9.2 months for responders and 5.3 months for non-
responders [5]. The response rates reported with FP range
from 35 to 40%, whereas the 2-year survival rates of
patients with locally advanced esophageal cancer range
from 8 to 55%, with a mean 27% [6–8]. To improve both
local and distant tumor control in patients with esophageal
carcinoma, new therapeutic regimens must be developed.
Recently, faborite antitumor effects of combination therapy
with ﬂuorouracil and taxen were reported. Docetaxel/S-1
combination is highly active and well tolerated in advanced
or recurrent gastric cancer [9], and those synergistic anti-
tumor activity has been fully elucidated [10].
As for advanced esophageal carcinoma, combination of
docetaxel and 5-FU with concurrent radiotherapy had good
efﬁcacy [11].
The taxanes have been shown to be active agents in the
treatment of esophageal carcinoma. Many studies have
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with locally advanced and metastatic esophageal carcino-
mas [12].
Docetaxel (TXT), cisplatin (CDDP), and 5-FU have
shown activity in upper gastrointestinal malignancies with
different mechanisms. In Europe, TXT, CDDP, and 5-FU
(DCF) combination therapy has been commonly used in
patients with advanced gastric cancer. In a report from the
V325 study group, advanced gastric or gastroesophageal
junction cancer patients receiving DCF not only had sta-
tistically improved overall survival and time to tumor
progression, but they also had better preservation of quality
of life compared with patients receiving FP therapy [13].
The addition of TXT to CDDP plus 5-FU is expected to
improve treatment outcomes for patients with esophageal
carcinoma.
When we were using combination therapy for advanced
esophageal squamous cell carcinoma based on the regimen
established by Ajani et al., as a pilot study, marked
myelosuppression occurred in all patients.
We therefore conducted a phase I clinical trial of DCF in
patients with advanced thoracic esophageal carcinoma with
T4 tumors and/or M1 staging with dividedly administration
of each drug into two blocks per one course. This phase I,
dose-escalation study of TXT, CDDP, and 5-FU was con-
ducted at the Department of Surgical Oncology, Gifu
University School of Medicine. The goal of this trial was to
determine the recommended dose (RD) for use in phase II
trials on the basis of the maximum tolerated dose (MTD)
and dose-limiting toxicity (DLT). Secondary objectives
were treatment-related toxicity and efﬁcacy.
Patients and methods
Patient eligibility criteria
To be eligible for the study, patients had to be at least
18 years of age at the time of registration and have histo-
logically or cytologically conﬁrmed squamous cell carci-
noma (SCC), which was surgically unresectable or
recurrent. They also had to have an EOCG performance
status of 0, 1, or 2, a life expectancy of[12 weeks, and
adequate liver, bone marrow, renal and cardiovascular
function (serum bilirubin B 1.5 mg/dl; neutrophil count
31,500/mm
3; serum aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) B twice the upper limit of
normal range; platelet count C10 9 10
4/mm
3; hemoglobin
C8.0 g/dl; and creatinine B1.2 mg/dl (or creatinine clear-
ance[60 ml/min). Patients previously treated with taxane
therapy for recurrent disease or irradiation to major bone
areas were excluded from the study. Finally, the last che-
motherapeutic treatment had to be at least 4 weeks before
trial enrollment. The major exclusion criteria included
serious concomitant illness, symptomatic infectious dis-
ease, severe drug allergy, symptomatic peripheral neurop-
athy, or uncontrolled diabetes mellitus. All the participants
had to sign an informed consent form approved by the
Ethical Committee of Gifu University Hospital before
study entry. Finally, 18 patients were entered, and all
patients had fully undergone DCF therapy.
Study design
The primary objectives of this phase I study were to
determine the MTD and toxicity of escalating doses of
TXT combined with a ﬁxed dose of CDDP and 5-FU in
patients with advanced esophageal carcinoma. The sec-
ondary objective of the study was to obtain preliminary
data regarding the clinical response.
At least three patients were entered at each TXT dose
level. There was no dose-escalation within individual
patients or within a dose level. All three patients at a
given dose level completed the ﬁrst two cycles of treat-
ment without DLT before further patients were enrolled in
the next dose level. In the absence of DLT, the next dose
level was explored. Doses were escalated in sequential
groups of three patients until the MTD was established or
the highest intended dose levels were reached. If any of
the three patients experienced DLT, an additional 3
patients were treated at the same dose level. If three or
more of the six patients at a given dose level experienced
DLT, the dose level was deﬁned as the MTD. The level
one step below was set as the RD for further evaluation in
a phase II study.
Treatment plan
Patients received TXT diluted in 250 ml of normal saline at
the assigned dose. It was infused intravenously (iv) over
2 h, and a maintenance infusion was given for the next 2 h.
Then CDDP was prepared in normal saline at a dose of
40 mg/m
2 and administered over 2 h on day 1.5-FU was
prepared in normal saline at a dose of 400 mg/m
2 and
administered continuously on days 1–5. TXT and CDDP
were given on days 1 and 15, and 5-FU was given on days
1–5 and 15–19 of every 28-day cycle. The dose-escalation
Table 1 Dose-escalation scheme
Dose level Docetaxel
(mg/m
2)
Cisplatin
(mg/m
2)
5FU
(mg/m
2)
1 30 40 400
2 35 40 400
3 40 40 400
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was 30 mg/m
2 (dose level I), and this was increased up to a
maximum of 40 mg/m
2 in 5 mg/m
2steps.
Supportive therapy for treatment and prophylaxis for
expected side effects was performed. All patients were
premedicated with granisetron 2 mg iv. Hypersensitivity
reactions were treated with prophylactic use of dexameth-
asone 8 mg iv, which was infused 1 h prior to the admin-
istration of TXT. Further dexamethasone was prescribed at
a dose of 4 mg orally for 2 days after administration of
TXT to reduce the risk of hypersensitivity reaction and
ﬂuid retention. Diuretics were added at the discretion of the
treating physician. Appropriate hydration was given before
and after the cisplatin infusion. Antiemetics were recom-
mended on subsequent days as needed.
To avoid severe mucositis, L-glutamine 8 g was
administrated for all patients.
Patient monitoring and response criteria
All patients underwent complete staging procedures to
document disease extent, including EOCG performance
status, medical history, and physical examination. Prestudy
laboratory evaluation including a complete blood cell
count; serum electrolytes; urea; creatinine and 24-h creat-
inine clearance; bilirubin; alkaline phosphatase and trans-
aminases; CEA, SCC, CA19-9 and CYFRA measurements,
and electrocardiogram was obtained within 1 week before
initiation of treatment and at the start of each treatment
cycle. Baseline computed tomography (CT) or magnetic
resonance imaging (MRI) scans and positron emission
tomography-CT were performed within 4 weeks prior to
study entry. All patients had a complete blood count taken
every week during therapy. Levels of electrolytes, serum
creatinine, transaminases, alkaline phosphatase and biliru-
bin, and plasma urea were measured every 2 weeks during
therapy. Medical history including toxicity, physical
examination, and toxicity assessment was graded every
2 weeks during the study according to the Common Ter-
minology Criteria for Adverse Events (v3.0). Tumor
measurements were made from radiographic ﬁlms or scans
taken to document treatment response during therapy and
were repeated at every second cycle of treatment or sooner
if the patient appeared to show disease progression. Tumor
response was assessed based on the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria [14]. The
response status of measurable lesions was evaluated by a
barium meal study, endoscopy, ultrasonography and CT, or
MRI.
A complete response was deﬁned as complete disap-
pearance of all clinically detectable malignant diseases. A
partial response was deﬁned as a C30% decrease in the
sum of the perpendicular diameters of all measurable
lesions lasting at least 4 weeks. Progressive disease was
deﬁned as C20% increase in the sum of products of mea-
surable lesions over the smallest sum observed or appear-
ance of new lesions. Stable disease did not qualify as
complete response, partial response, or progressive disease.
Deﬁnition of dose-limiting toxicity and criteria
for dose modiﬁcations
Toxicity was evaluated and scored according to the Com-
mon Terminology Criteria for Adverse Events (v3.0). DLT
was deﬁned as febrile grade 3 neutropenia, grade 4 neu-
tropenia lasting [7 days, grade 3 leucopenia, grade 4
thrombocytopenia, or grade 3 thrombocytopenia with
bleeding tendency, or any grade 3–4 non-hematological
toxicity with the exceptions of nausea, vomiting, diarrhea,
and alopecia. If hematological toxicity C grade 3 occurred,
administration of the therapy was delayed until the platelet
count was 10 9 10
4/mm
3 and absolute neutrophils were
C2 9 10
3. If gastrointestinal toxicity C grade 3 occurred,
the administration of chemotherapy was delayed until the
optimum dose could be tolerated. Treatment was repeated
every 4 weeks or as soon as a patient had recovered from
the toxicity of the previous chemotherapy. However, if
toxicities persisted for more than 2 weeks following the
time of planned treatment, the patient was removed from
the study. A delay longer than 2 weeks in administering the
second cycle of therapy was also considered a DLT. Dose
modiﬁcations for the next dose were based on the most
severe toxicity observed since the previous treatment
course. Treatment was interrupted until toxicity resolved to
B grade 1.
Results
Patient characteristics
Between October 2008 and December 2009, 18 patients
were entered into the present study. Demographic and
clinical characteristics of the study population are sum-
marized in Table 2. Three dose levels were evaluated. The
patients received a total of 70 courses of chemotherapy,
with the median number of courses administered per
patient being 3.9 (range, 2–6). All patients in the study had
locally advanced esophageal carcinoma or metastatic
lesions. Median patient age was 62.8 years (range,
50–79 years). All patients had an ECOG performance
status (PS) of 0–1. Histology showed moderately well-
differentiated carcinoma in 38.9% of the patients and
poorly differentiated carcinoma in 16.7%.
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Data on the dose-escalation scheme, DLT, and response are
summarized in Table 3. Only Cgrade 2 toxicity data were
collected and reported. Especially for neutropenia and
leucopenia, only Cgrade 3 toxicity data were reported.
Patient characteristics were well balanced across all dose
levels. No treatment-related deaths occurred.
A total of six patients were initially administered the
level 1 dose (TXT 30 mg/m
2). One patient had grade 3
neutropenia lasting 5 days with fever. Three patients were
added to the cohort at this dose level. Of the six patients
treated at dose level 1, 2 had grade 3 neutropenia with fever
lasting 5 days, 1 had grade 2 anemia, and 1 had grade 2
thrombocytopenia. Three patients had grade 2 anorexia, 1
had grade 2 fatigue, 1 had grade 2 nausea, and 2 had grade
2 mucositis. Twenty-four courses of chemotherapy were
evaluated. Among the six patients entered at this dose
level, ﬁve responders were observed.
Three patients were initially enrolled at dose level 2
(TXT 35 mg/m
2). One patient had grade 3 neutropenia
lasting 5 days with fever. Three additional patients were
enrolled at this dose level, resulting in six patients being
treated at this dose level. One patient had grade 3 neutro-
penia lasting 5 days with fever, 1 had grade 3 anemia, 1
experienced grade 2 nausea, two experienced grade 2
anorexia, one had grade 1 mucositis, and one patient
experienced grade 2 sensory neuropathy. Twenty-seven
courses of chemotherapy were administered at dose level 2.
All six of the patients entered at this dose level were
responders.
At dose level 3 (TXT 40 mg/m
2), 1 of 3 patients
developed grade 3 toxicity characterized by febrile neu-
tropenia, so three patients were added to the cohort at this
dose level. Of the six patients treated at this dose level, one
had grade 3 leucopenia, two had grade 3 febrile neutro-
penia, two experienced grade 2 nausea, two experienced
grade 2 anorexia, and one had grade 2 mucositis. This dose
(TXT 40 mg/m
2) was considered the MTD; therefore, the
dose of TXT for further phase II studies was determined to
be 35 mg/m
2 administered biweekly.
Frequency of treatment-related toxicities is summarized
in Table 4. Grade 3 leucopenia occurred in one patient
(5.6%). Febrile neutropenia (grade 3) was common and
occurred in ﬁve patients (27.8%). Grade 2 nausea occurred
in ﬁve patients (27.8%), and grade 1/2 mucositis occurred
in two patients (11.1%). Alopecia was observed in 100% of
patients. Five courses of chemotherapy (7%) were delayed
for 1 week due to myelosuppression.
Table 2 Characteristics of patients
Characteristics No. %
No. of patients 18
Age, years
Median 62.8
Range 50–79
Sex
Males 15 83.3
Females 3 16.7
Performance status
0–1 18 100
20 0
Disease status
Locally advanced 9 50
Locally advanced and metastatic 9 50
Stage of disease
T3N1M0 2 11.1
T3N2M0 4 22.2
T3N4M0 3 16.7
T3N4M1 3 16.7
T4N1M1 4 22.2
T4N2M1 2 11.1
Site of primary disease
Ut 4 22.2
Mt 9 50.0
Lt 5 27.8
Differentiation
Well differentiated 7 38.9
Moderately differentiated 8 44.4
Poorly differentiated 3 16.7
Table 3 Dose-escalation scheme, dose-limiting toxicity, and response
Dose level of docetaxel Patients Cycles DLT Type Response
30 mg/m
2 6 24 2 2 Febrile neutropenia 2 CR, 3 PR,1 PD
35 mg/m
2 6 27 2 1 Febrile neutropenia 3 CR, 3 PR
1 Anemia
40 mg/m
2 6 19 3 2 Febrile neutropenia 1 CR, 4 PR,1 SD
1 Neutropenia
Total 18 70 7 Response rate: 88.9%
DLT dose-limiting toxicity, CR complete response, PR partial response, SD stable disease, PD progressive disease
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Although response to therapy was not the endpoint of this
study, patients who had completed at least two cycles of
chemotherapy were evaluated for radiographical response.
There were six patients with complete response: two
patients received two cycles for a locally advanced
esophageal cancer and underwent complete resection
(histological grades 2 and 3), and four patients received
2–9 cycles for metastatic esophageal cancer (lung, two
cases; liver, one case; lung and liver, one case).
Of the 10 patients with partial response, four patients
stopped therapy after receiving two or three cycles and
underwent surgical curative resection. One patient with
stable disease for metastatic esophageal cancer maintained
disease stability over ﬁve treatment cycles. One patient had
documented progressive disease after three cycles with
metastatic carcinoma to the liver. The response rate was
88.9%, with six patients (33.3%) achieving a complete
response and 10 patients (55.6%) a partial response. Dis-
ease stability and progression were observed in two
patients (11.1%). No patient discontinued study therapy
due to toxicity. Responses were observed at all dose levels,
indicating a wide margin of activity for this regimen.
Discussion
The present study was designed to establish a safe and
tolerable dose of TXT (Taxotere; Sanoﬁ-Aventis, Paris,
France) when administered in combination with ﬁxed doses
of CDDP and 5-FU. TXT is a semi-synthetic taxoid derived
from the European yew tree, Taxus baccata. The taxanes
enhance polymerization of tubulin into stable microtubule
formation and inhibit their tubulin depolymerization by
blocking the cell cycle in metaphase, anaphase, and inter-
phase [15]. This inhibition may improve the efﬁcacy of
drugs such as CDDP, which are active in all phases of the
cell cycle via direct DNA damage. Furthermore, the
taxanes increase programmed cell death, and TXT
appears to be more potent than paclitaxel in inhibiting
angiogenesis [16].
TXT, CDDP, and 5-FU activity occurs by synergistic or
non-cross-resistance effects when administered in combi-
nation. Previously published studies have shown that the
DCF combination demonstrates considerable activity. A
49% response rate was observed with a DCF combination
treating patients with locally advanced esophageal
SCC [3].
In the present study, a total of 70 courses of chemo-
therapy were administered to the 18 patients, and responses
were observed at all dose levels. No treatment-related
deaths were observed. Toxicity of TXT was encountered at
all dose levels, indicating that the pharmacokinetics of this
drug may vary in different individuals.
TXT offers favorable outcomes, although it has adverse
hematological toxicity. Neutropenia occurs approximately
8–10 days after administration but recovers rapidly. TXT
75–100 mg/m
2 every 3–4 weeks is associated with a quite
pronounced neutropenia, with an up to 44% rate of febrile
neutropenia in patients with recurrent ovarian cancer [17].
Takahashi et al. reported that the major toxicity of DCF,
repeated every 3 weeks at doses of TXT 50 mg/m
2, CDDP
70 mg/m
2, and 5-FU 700 mg/m
2, was myelosuppression
Table 4 Frequency of
treatment-related toxicity
CTCAE ver. 3 common toxicity criteria
Dose level 1 N = 6 Dose level 2 N = 6 Dose level 3 N = 6
Hematologic
Febrile neutropenia 2 (grade 3) 1 (grade 3) 2 (grade 3)
Leucopenia 0 0 1 (grade 3)
Anemia 1 (grade 2) 1 (grade 3) 0
Thrombocytopenia 1 (grade 2) 0 0
Non-hematologic
Anorexia 3 (grade 2) 2 (grade 2) 2 (grade 2)
Fatigue 1 (grade 2) 0 0
Mucositis 0 1 (grade 1) 1 (grade 2)
Nausea/vomiting 1 (grade 2) 1 (grade 2) 2 (grade 2)
Diarrhea 0 1 (grade 2) 0
Pericardial effusion 0 0 1 (grade 1)
Alopecia 4 (grade 1) 3 (grade 1) 5 (grade 1)
1 (grade 2) 3 (grade 2) 1 (grade 2)
Edema 1 (grade 2) 1 (grade 2) 1 (grade 2)
Sensory neuropathy 0 1 (grade 2) 0
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tropenia in a phase II study were 53.8 and 43.6%, respec-
tively [18].
To minimize toxicity and maximize dose intensity, we
elected to investigate a biweekly regimen of TXT with a
40-mg/m
2 ﬁxed dose of CDDP and a 400-mg/m
2 ﬁxed dose
of 5-FU. Compared with the results of a phase I/II study of
a TXT-containing regimen for esophageal cancer [18], our
regimen included greater TXT dose intensity than the
triweekly administration of TXT performed in that study.
Divided administration of TXT and CDDP may reduce
myelosuppression and neuropathy, while maintaining
almost unchanged efﬁcacy.
The median white blood cell and platelet count nadir
occurred on day 9 (range 4–18 days), with a median
hematological recovery observed by day 12. Neutropenic
fever requiring hospitalization was observed in two
patients. Only one patient required a blood transfusion for
anemia, and no thrombocytopenia3grade 3 was seen.
The incidence of TXT-speciﬁc toxicities, such as
neurotoxicity and acute hypersensitivity reactions, was
relatively low and did not appear to be a major clinical
problem, so a reduction in dose is generally not required.
This was probably due to the low cumulative dose (espe-
cially with the biweekly dose method) of TXT and CDDP
administered.
Fluid retention manifesting as peripheral edema, pleural
effusion, or ascites was cumulative in incidence and
severity. One patient had grade 4 body-weight gain that
required diuretics.
Patients receiving more than 50 mg/m
2 of CDDP may
suffer nausea and vomiting [19]. Both are frequent side
effects caused by administration of CDDP and can be well
controlled by administration of granisetron and dexametha-
sone. Grade 1/2 alopecia was observed in all patients in the
present study. Of note, no patient in our study experienced
grade 3 or 4 mucositis, likely due to the great care paid to
daily supplementation with L-glutamine 8 g, which con-
tributed to the low toxicity proﬁle of this regimen.
Five patients underwent radical surgical resection, with
a postoperative mortality of 0%. Pathologically conﬁrmed
complete response was documented in one patient. Loco-
regional disease control was achieved in 88.9% of the
patients in the present study. The results emerging from
this phase I study with TXT are particularly encouraging.
In the present study, all the 18 patients were diagnosed as
squamous cell carcinoma, whereas most esophageal car-
cinomas in western populations are diagnosed as adeno-
carcinoma [20]. Given that squamous cell carcinoma and
adenocarcinoma are distinct pathologic entity, molecular
analyses using cell lines or tissue samples are needed to
evaluate the validity that this regimen can be applied to
esophageal adenocarcinoma.
In conclusion, the recommended DCF combination dose
in the present study was determined to be TXT 35 mg/m
2
with CDDP 40 mg/m
2 and 5-Fu 400 mg/m
2, administered
biweekly. We found that this regimen showed high acti-
vation and tolerance such that it could be offered as a
candidate component of standard regimens for treating
advanced esophageal carcinoma. A phase II study has
already been started. Further clinical trials using this
combination should be pursued in the treatment of
advanced esophageal carcinoma.
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